Study confirms difference in radical prostatectomy outcomes between surgeons

March 18, 2013, European Association of Urology

New evidence from Sweden confirms previous studies which suggest that functional outcomes after radical prostatectomy may vary between surgeons, especially in relation to continence. However, the group found no evidence of heterogeneity in potency-related outcomes.

The results of this investigation, to be presented at the 28th Annual EAU Congress, aimed of to examine between surgeon variation with regards to oncological and patient-reported functional outcomes in one European centre.

The study included 1280 men who underwent open performed by one of nine surgeons at an academic institution in Sweden between 2 January 2001 through 16 July 2008.

Biochemical recurrence was defined as a prostate-specific antigen (PSA) value > 0.2 ng/ml with at least one confirmatory rise. The scientists measured functional outcomes preoperatively and postoperatively 18 months after the procedure by patient-administered questionnaires. Multivariate random effect models were used to evaluate between surgeons, adjusting for case mix – which included age, PSA, pathological stage and grade - year of surgery and .

Of 635 men potent at baseline, 606 provided data at 18 months, of whom 100/606 (17%) were potent (nerve-sparing and non-nerve-sparing surgery), suggesting the absence of heterogeneity between surgeons (p=0.5).

The continence rate at 18 months was 85%, revealing statistically significant heterogeneity between surgeons (p=0.002). There was evidence of an unexpected negative correlation between the surgeons' adjusted probabilities of potency and continence at 18 months. At the same time, the researchers did not find any association between surgeons' adjusted probabilities of and 5-year probability of freedom from biochemical recurrence.

"Surgeon heterogeneity suggests that at least some patients are receiving suboptimal care," write the authors. "Quality assurance measures should be considered to identify and correct suboptimal treatments to ensure patients receive optimal care."

Explore further: Want to avoid ED following prostate cancer surgery? Find an experienced, gentle surgeon

More information: S. Carlsson, et al., "Effects of surgeon variability on oncological and functional outcomes in a population-based setting," Abstract Nr: 808; 28th Annual EAU Congress, 15 to 19 March 2013; Milan, Italy.

Related Stories

Want to avoid ED following prostate cancer surgery? Find an experienced, gentle surgeon

May 16, 2012
Prostate cancer is the most commonly diagnosed non-skin cancer in the U.S., and radical prostatectomy, the surgical removal of the prostate gland, remains the most popular therapeutic option, accounting for half of treatments.

Centralization to fewer surgeons results in better survival after esophageal cancer surgery

January 7, 2013
Patients who undergo surgery for oesophageal cancer have a much greater chance of long term survival if the operation is carried out by a surgeon who has performed this particular operation many times before. This according ...

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.